Cargando…

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

BACKGROUND: Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ascierto, Maria Libera, Worschech, Andrea, Yu, Zhiya, Adams, Sharon, Reinboth, Jennifer, Chen, Nanhai G, Pos, Zoltan, Roychoudhuri, Rahul, Di Pasquale, Giovanni, Bedognetti, Davide, Uccellini, Lorenzo, Rossano, Fabio, Ascierto, Paolo A, Stroncek, David F, Restifo, Nicholas P, Wang, Ena, Szalay, Aladar A, Marincola, Francesco M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213037/ https://www.ncbi.nlm.nih.gov/pubmed/22011439 http://dx.doi.org/10.1186/1471-2407-11-451

Ejemplares similares

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
por: Worschech, Andrea, et al.
Publicado: (2009)

The stable traits of melanoma genetics: an alternate approach to target discovery
por: Spivey, Tara L, et al.
Publicado: (2012)

Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells
por: Wang, Huiqiang, et al.
Publicado: (2012)

The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation
por: Zhang, Qian, et al.
Publicado: (2009)

The immune‐related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2014)

The immune-related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2015)

Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68
por: Ehrig, Klaas, et al.
Publicado: (2013)

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2010)

Regression of Human Prostate Tumors and Metastases in Nude Mice following Treatment with the Recombinant Oncolytic Vaccinia Virus GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2010)

IRF-1 responsiveness to immune cytokines predicts different cancer phenotypes
por: Murtas, Daniela, et al.
Publicado: (2013)

Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice
por: Donat, Ulrike, et al.
Publicado: (2012)

Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection
por: Weibel, Stephanie, et al.
Publicado: (2011)

Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68
por: Gentschev, Ivaylo, et al.
Publicado: (2011)

Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy
por: Adelfinger, Marion, et al.
Publicado: (2014)

Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer
por: Gholami, Sepideh, et al.
Publicado: (2013)

Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population
por: Tomei, Sara, et al.
Publicado: (2012)

Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody
por: Patil, Sandeep S., et al.
Publicado: (2012)

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
por: Adelfinger, Marion, et al.
Publicado: (2015)

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes
por: Murtas, D, et al.
Publicado: (2013)

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
por: Gowda, Madhu, et al.
Publicado: (2011)

An immunologic portrait of cancer
por: Ascierto, Maria Libera, et al.
Publicado: (2011)

Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps
por: Kober, Christina, et al.
Publicado: (2015)

Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice
por: Chen, Nanhai G, et al.
Publicado: (2011)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
por: Chen, Nanhai, et al.
Publicado: (2013)

Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis
por: Spivey, Tara L, et al.
Publicado: (2011)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy
por: Huang, Ting, et al.
Publicado: (2015)

Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors
por: Schäfer, Simon, et al.
Publicado: (2012)

Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival
por: Duggal, Rohit, et al.
Publicado: (2013)

Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA
por: Seubert, C M, et al.
Publicado: (2011)

Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine
por: Binz, Eike, et al.
Publicado: (2017)

Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy
por: Haddad, Dana, et al.
Publicado: (2016)

GM-CSF/IL-3/IL-5 receptor common β chain (CD131) expression as a biomarker of antigen-stimulated CD8(+ )T cells
por: Selleri, Silvia, et al.
Publicado: (2008)

IRF5 gene polymorphisms in melanoma
por: Uccellini, Lorenzo, et al.
Publicado: (2012)

Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice
por: Hofmann, Elisabeth, et al.
Publicado: (2014)

HLA class I and II genotype of the NCI-60 cell lines
por: Adams, Sharon, et al.
Publicado: (2005)

Optical Detection and Virotherapy of Live Metastatic Tumor Cells in Body Fluids with Vaccinia Strains
por: Wang, Huiqiang, et al.
Publicado: (2013)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms
por: Kloker, Linus D., et al.
Publicado: (2020)

Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
por: Gentschev, Ivaylo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gs9ff2nrt48slm3i4dc5qgckc4